Intellia Therapeutics Inc buy Savour
Start price
24.01.21
/
20%
€63.50
Target price
24.01.22
-
Performance (%)
-15.72%
End price
11.03.21
€53.52
Summary
This prediction ended on 11.03.21 with a price of €53.52. The prediction for Intellia Therapeutics Inc disappointed with a performance of -15.72%. Savour has 20% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | -1.907% | -1.907% | -6.728% | -75.168% |
| iShares Core DAX® | 2.591% | 2.467% | 8.839% | 55.552% |
| iShares Nasdaq 100 | -0.915% | -6.458% | 24.933% | 73.037% |
| iShares Nikkei 225® | 0.145% | -8.773% | 47.385% | 63.781% |
| iShares S&P 500 | -0.367% | -1.220% | 21.667% | 61.027% |
According to Savour what are the pros and cons of Intellia Therapeutics Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by Savour for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Buy Intellia Therapeutics Inc